130 related articles for article (PubMed ID: 16951220)
1. Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.
Nguyen DM; Sam K; Tsimelzon A; Li X; Wong H; Mohsin S; Clark GM; Hilsenbeck SG; Elledge RM; Allred DC; O'Connell P; Chang JC
Clin Cancer Res; 2006 Sep; 12(17):5047-54. PubMed ID: 16951220
[TBL] [Abstract][Full Text] [Related]
2. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ; Van der Auwera I; Van den Eynden GG; Elst HJ; Weyler J; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3249-56. PubMed ID: 16740744
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG; Van Laere SJ; Van der Auwera I; Merajver SD; Van Marck EA; van Dam P; Vermeulen PB; Dirix LY; van Golen KL
Breast Cancer Res Treat; 2006 Feb; 95(3):219-28. PubMed ID: 16244790
[TBL] [Abstract][Full Text] [Related]
4. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
5. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis.
Van Laere S; Van der Auwera I; Van den Eynden GG; Fox SB; Bianchi F; Harris AL; van Dam P; Van Marck EA; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2005 Oct; 93(3):237-46. PubMed ID: 16172796
[TBL] [Abstract][Full Text] [Related]
6. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
[TBL] [Abstract][Full Text] [Related]
7. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
McCarthy NJ; Yang X; Linnoila IR; Merino MJ; Hewitt SM; Parr AL; Paik S; Steinberg SM; Hartmann DP; Mourali N; Levine PH; Swain SM
Clin Cancer Res; 2002 Dec; 8(12):3857-62. PubMed ID: 12473600
[TBL] [Abstract][Full Text] [Related]
8. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.
Van Laere S; Beissbarth T; Van der Auwera I; Van den Eynden G; Trinh XB; Elst H; Van Hummelen P; van Dam P; Van Marck E; Vermeulen P; Dirix L
Clin Cancer Res; 2008 Nov; 14(22):7452-60. PubMed ID: 19010862
[TBL] [Abstract][Full Text] [Related]
9. cDNA microarray analysis of inflammatory breast cancer signatures.
Laere SJ; Vermeulen PB; Dirix LY
Methods Mol Biol; 2009; 512():71-98. PubMed ID: 19347274
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy.
Bertucci F; Finetti P; Rougemont J; Charafe-Jauffret E; Nasser V; Loriod B; Camerlo J; Tagett R; Tarpin C; Houvenaeghel G; Nguyen C; Maraninchi D; Jacquemier J; Houlgatte R; Birnbaum D; Viens P
Cancer Res; 2004 Dec; 64(23):8558-65. PubMed ID: 15574762
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of inflammatory breast cancer.
Bertucci F; Finetti P; Birnbaum D; Viens P
Cancer; 2010 Jun; 116(11 Suppl):2783-93. PubMed ID: 20503410
[TBL] [Abstract][Full Text] [Related]
12. Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis.
Van Laere S; Van der Auwera I; Van den Eynden G; Van Hummelen P; van Dam P; Van Marck E; Vermeulen PB; Dirix L
Br J Cancer; 2007 Oct; 97(8):1165-74. PubMed ID: 17848951
[TBL] [Abstract][Full Text] [Related]
13. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue.
Mina L; Soule SE; Badve S; Baehner FL; Baker J; Cronin M; Watson D; Liu ML; Sledge GW; Shak S; Miller KD
Breast Cancer Res Treat; 2007 Jun; 103(2):197-208. PubMed ID: 17039265
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.
Andre F; Job B; Dessen P; Tordai A; Michiels S; Liedtke C; Richon C; Yan K; Wang B; Vassal G; Delaloge S; Hortobagyi GN; Symmans WF; Lazar V; Pusztai L
Clin Cancer Res; 2009 Jan; 15(2):441-51. PubMed ID: 19147748
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic molecular classification of breast cancers based on gene expression profiling].
Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740
[TBL] [Abstract][Full Text] [Related]
16. Two prognostic groups of inflammatory breast cancer have distinct genotypes.
Lerebours F; Bertheau P; Bieche I; Plassa LF; Champeme MH; Hacene K; Toulas C; Espie M; Marty M; Lidereau R
Clin Cancer Res; 2003 Sep; 9(11):4184-9. PubMed ID: 14519644
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level.
Martínez-Arribas F; Alvarez T; Del Val G; Martín-Garabato E; Núñez-Villar MJ; Lucas R; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2007; 27(1A):219-22. PubMed ID: 17352236
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
20. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
